Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Global blood preparation industry 3600 synopsis, 2014 - 2025
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Application trends
2.1.4. Regional trends
Chapter 3. Blood Preparation Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 – 2025
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Growing prevalence of diseases requiring blood transfusion
3.3.1.2. Rising applications of blood derivatives
3.3.1.3. Increasing awareness about blood donations in developing countries
3.3.2. Industry pitfalls & challenges
3.3.2.1. Risk of infection transmission through transfused blood
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By application
3.5. Industry eco-system
3.5.1. Supply chain analysis
3.6. Regulatory landscape
3.6.1. U.S
3.6.2. Europe
3.7. Porter’s analysis
3.8. Competitive landscape, 2018
3.8.1. Strategy dashboard
3.9. PESTEL analysis
Chapter 4. Blood Preparation Market, By Product
4.1. Key segment trends
4.2. Blood and blood components
4.2.1. Market size, by region, 2014 - 2025
4.2.2. Whole blood
4.2.2.1. Market size, by region, 2014 - 2025
4.2.3. Blood components
4.2.3.1. Market size, by region, 2014 - 2025
4.2.3.2. Red Blood Cells
4.2.3.2.1. Market size, by region, 2014 - 2025
4.2.3.3. Platelets
4.2.3.3.1. Market size, by region, 2014 - 2025
4.2.3.4. Plasma
4.2.3.4.1. Market size, by region, 2014 - 2025
4.2.3.5. White blood cells
4.2.3.5.1. Market size, by region, 2014 - 2025
4.3. Anti-thrombotic and anticoagulants
4.3.1. Market size, by region, 2014 - 2025
4.3.2. Platelet aggregation inhibitors
4.3.2.1. Market size, by region, 2014 - 2025
4.3.2.2. Glycoprotein inhibitors
4.3.2.2.1. Market size, by region, 2014 - 2025
4.3.2.3. COX inhibitors
4.3.2.3.1. Market size, by region, 2014 - 2025
4.3.2.4. ADP antagonists
4.3.2.4.1. Market size, by region, 2014 - 2025
4.3.2.5. Phosphodiesterase inhibitors
4.3.2.5.1. Market size, by region, 2014 - 2025
4.3.2.6. Others
4.3.2.6.1. Market size, by region, 2014 - 2025
4.3.3. Fibrinolytics
4.3.3.1. Market size, by region, 2014 - 2025
4.3.4. Anticoagulants
4.3.4.1. Market size, by region, 2014 – 2025
4.3.4.2. Heparins
4.3.4.2.1. Market size, by region, 2014 – 2025
4.3.4.2.2. Unfractionated heparin
4.3.4.2.2.1. Market size, by region, 2014 – 2025
4.3.4.2.3. Low molecular weight heparin (LMWH)
4.3.4.2.3.1. Market size, by region, 2014 – 2025
4.3.4.2.4. Ultra-low molecular weight heparin
4.3.4.2.4.1. Market size, by region, 2014 – 2025
4.3.4.3. Vitamin K antagonists
4.3.4.3.1. Market size, by region, 2014 – 2025
4.3.4.4. Direct thrombin inhibitors
4.3.4.4.1. Market size, by region, 2014 – 2025
4.3.4.5. Direct factor Xa inhibitors
4.3.4.5.1. Market size, by region, 2014 – 2025
Chapter 5. Blood Preparation Market, By Application
5.1. Key segment trends
5.2. Thrombocytosis
5.2.1. Market size, by region, 2014 - 2025
5.3. Pulmonary embolism
5.3.1. Market size, by region, 2014 – 2025
5.4. Renal impairment
5.4.1. Market size, by region, 2014 – 2025
5.5. Angina blood vessel complications
5.5.1. Market size, by region, 2014 – 2025
5.6. Others
5.6.1. Market size, by region, 2014 – 2025
Chapter 6. Blood Preparation Market, By Region
6.1. Key regional trends
6.2. North America
6.2.1. Market size, by country, 2014 – 2025
6.2.2. Market size, by product, 2014 – 2025
6.2.2.1. Market size, by blood and blood components, 2014 – 2025
6.2.2.1.1. Market size, by blood components, 2014 – 2025
6.2.2.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.2.2.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.2.2.2.2. Market size, by anti-coagulants, 2014 – 2025
6.2.2.2.2.1. Market size, by heparins, 2014 – 2025
6.2.3. Market size, by application, 2014 – 2025
6.2.4. U.S.
6.2.4.1. Market size, by product, 2014 – 2025
6.2.4.1.1. Market size, by blood and blood components, 2014 – 2025
6.2.4.1.1.1. Market size, by blood components, 2014 – 2025
6.2.4.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.2.4.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.2.4.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.2.4.1.2.2.1. Market size, by heparins, 2014 – 2025
6.2.4.2. Market size, by application, 2014 – 2025
6.2.5. Canada
6.2.5.1. Market size, by product, 2014 – 2025
6.2.5.1.1. Market size, by blood and blood components, 2014 – 2025
6.2.5.1.1.1. Market size, by blood components, 2014 – 2025
6.2.5.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.2.5.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.2.5.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.2.5.1.2.2.1. Market size, by heparins, 2014 – 2025
6.2.5.2. Market size, by application, 2014 – 2025
6.3. Europe
6.3.1. Market size, by country, 2014 – 2025
6.3.2. Market size, by product, 2014 – 2025
6.3.2.1. Market size, by blood and blood components, 2014 – 2025
6.3.2.1.1. Market size, by blood components, 2014 – 2025
6.3.2.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.2.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.2.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.2.2.2.1. Market size, by heparins, 2014 – 2025
6.3.3. Market size, by application, 2014 – 2025
6.3.4. Germany
6.3.4.1. Market size, by product, 2014 – 2025
6.3.4.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.4.1.1.1. Market size, by blood components, 2014 – 2025
6.3.4.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.4.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.4.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.4.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.4.2. Market size, by application, 2014 – 2025
6.3.5. UK
6.3.5.1. Market size, by product, 2014 – 2025
6.3.5.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.5.1.1.1. Market size, by blood components, 2014 – 2025
6.3.5.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.5.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.5.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.5.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.5.2. Market size, by application, 2014 – 2025
6.3.6. France
6.3.6.1. Market size, by product, 2014 – 2025
6.3.6.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.6.1.1.1. Market size, by blood components, 2014 – 2025
6.3.6.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.6.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.6.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.6.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.6.2. Market size, by application, 2014 – 2025
6.3.7. Spain
6.3.7.1. Market size, by product, 2014 – 2025
6.3.7.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.7.1.1.1. Market size, by blood components, 2014 – 2025
6.3.7.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.7.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.7.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.7.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.7.2. Market size, by application, 2014 – 2025
6.3.8. Italy
6.3.8.1. Market size, by product, 2014 – 2025
6.3.8.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.8.1.1.1. Market size, by blood components, 2014 – 2025
6.3.8.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.8.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.8.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.8.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.8.2. Market size, by application, 2014 – 2025
6.3.9. Russia
6.3.9.1. Market size, by product, 2014 – 2025
6.3.9.1.1. Market size, by blood and blood components, 2014 – 2025
6.3.9.1.1.1. Market size, by blood components, 2014 – 2025
6.3.9.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.3.9.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.3.9.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.3.9.1.2.2.1. Market size, by heparins, 2014 – 2025
6.3.9.2. Market size, by application, 2014 – 2025
6.4. Asia Pacific
6.4.1. Market size, by country, 2014 – 2025
6.4.2. Market size, by product, 2014 – 2025
6.4.2.1. Market size, by blood and blood components, 2014 – 2025
6.4.2.1.1. Market size, by blood components, 2014 – 2025
6.4.2.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.4.2.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.4.2.2.2. Market size, by anti-coagulants, 2014 – 2025
6.4.2.2.2.1. Market size, by heparins, 2014 – 2025
6.4.3. Market size, by application, 2014 – 2025
6.4.4. China
6.4.4.1. Market size, by product, 2014 – 2025
6.4.4.1.1. Market size, by blood and blood components, 2014 – 2025
6.4.4.1.1.1. Market size, by blood components, 2014 – 2025
6.4.4.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.4.4.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.4.4.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.4.4.1.2.2.1. Market size, by heparins, 2014 – 2025
6.4.4.2. Market size, by application, 2014 – 2025
6.4.5. India
6.4.5.1. Market size, by product, 2014 – 2025
6.4.5.1.1. Market size, by blood and blood components, 2014 – 2025
6.4.5.1.1.1. Market size, by blood components, 2014 – 2025
6.4.5.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.4.5.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.4.5.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.4.5.1.2.2.1. Market size, by heparins, 2014 – 2025
6.4.5.2. Market size, by application, 2014 – 2025
6.4.6. Japan
6.4.6.1. Market size, by product, 2014 – 2025
6.4.6.1.1. Market size, by blood and blood components, 2014 – 2025
6.4.6.1.1.1. Market size, by blood components, 2014 – 2025
6.4.6.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.4.6.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.4.6.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.4.6.1.2.2.1. Market size, by heparins, 2014 – 2025
6.4.6.2. Market size, by application, 2014 – 2025
6.5. Latin America
6.5.1. Market size, by country, 2014 – 2025
6.5.2. Market size, by product, 2014 – 2025
6.5.2.1. Market size, by blood and blood components, 2014 – 2025
6.5.2.1.1. Market size, by blood components, 2014 – 2025
6.5.2.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.5.2.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.5.2.2.2. Market size, by anti-coagulants, 2014 – 2025
6.5.2.2.2.1. Market size, by heparins, 2014 – 2025
6.5.3. Market size, by application, 2014 – 2025
6.5.4. Brazil
6.5.4.1. Market size, by product, 2014 – 2025
6.5.4.1.1. Market size, by blood and blood components, 2014 – 2025
6.5.4.1.1.1. Market size, by blood components, 2014 – 2025
6.5.4.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.5.4.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.5.4.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.5.4.1.2.2.1. Market size, by heparins, 2014 – 2025
6.5.4.2. Market size, by application, 2014 – 2025
6.5.5. Mexico
6.5.5.1. Market size, by product, 2014 – 2025
6.5.5.1.1. Market size, by blood and blood components, 2014 – 2025
6.5.5.1.1.1. Market size, by blood components, 2014 – 2025
6.5.5.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.5.5.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.5.5.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.5.5.1.2.2.1. Market size, by heparins, 2014 – 2025
6.5.5.2. Market size, by application, 2014 – 2025
6.6. Middle East & Africa
6.6.1. Market size, by country, 2014 – 2025
6.6.2. Market size, by product, 2014 – 2025
6.6.2.1. Market size, by blood and blood components, 2014 – 2025
6.6.2.1.1. Market size, by blood components, 2014 – 2025
6.6.2.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.6.2.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.6.2.2.2. Market size, by anti-coagulants, 2014 – 2025
6.6.2.2.2.1. Market size, by heparins, 2014 – 2025
6.6.3. Market size, by application, 2014 – 2025
6.6.4. South Africa
6.6.4.1. Market size, by product, 2014 – 2025
6.6.4.1.1. Market size, by blood and blood components, 2014 – 2025
6.6.4.1.1.1. Market size, by blood components, 2014 – 2025
6.6.4.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.6.4.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.6.4.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.6.4.1.2.2.1. Market size, by heparins, 2014 – 2025
6.6.4.2. Market size, by application, 2014 – 2025
6.6.5. Saudi Arabia
6.6.5.1. Market size, by product, 2014 – 2025
6.6.5.1.1. Market size, by blood and blood components, 2014 – 2025
6.6.5.1.1.1. Market size, by blood components, 2014 – 2025
6.6.5.1.2. Market size, by anti-thrombotic and anticoagulants, by type, 2014 – 2025
6.6.5.1.2.1. Market size, by platelet aggregation inhibitors, 2014 – 2025
6.6.5.1.2.2. Market size, by anti-coagulants, 2014 – 2025
6.6.5.1.2.2.1. Market size, by heparins, 2014 – 2025
6.6.5.2. Market size, by application, 2014 – 2025
Chapter 7. Company Profiles
7.1. Aralez Pharmaceuticals
7.1.1. Business overview
7.1.2. Financial data
7.1.3. Product landscape
7.1.4. Strategic outlook
7.1.5. SWOT analysis
7.2. AstraZeneca
7.2.1. Business overview
7.2.2. Financial data
7.2.3. Product landscape
7.2.4. Strategic outlook
7.2.5. SWOT analysis
7.3. Boehringer Ingelheim
7.3.1. Business overview
7.3.2. Financial data
7.3.3. Product landscape
7.3.4. Strategic outlook
7.3.5. SWOT analysis
7.4. Bristol-Myers Squibb
7.4.1. Business overview
7.4.2. Financial data
7.4.3. Product landscape
7.4.4. Strategic outlook
7.4.5. SWOT analysis
7.5. Daiichi Sankyo
7.5.1. Business overview
7.5.2. Financial data
7.5.3. Product landscape
7.5.4. Strategic outlook
7.5.5. SWOT analysis
7.6. GlaxoSmithKline PLC
7.6.1. Business overview
7.6.2. Financial data
7.6.3. Product landscape
7.6.4. Strategic outlook
7.6.5. SWOT analysis
7.7. Johnson and Johnson
7.7.1. Business overview
7.7.2. Financial data
7.7.3. Product landscape
7.7.4. Strategic outlook
7.7.5. SWOT analysis
7.8. Leo Pharma
7.8.1. Business overview
7.8.2. Financial data
7.8.3. Product landscape
7.8.4. Strategic outlook
7.8.5. SWOT analysis
7.9. Pfizer
7.9.1. Business overview
7.9.2. Financial data
7.9.3. Product landscape
7.9.4. Strategic outlook
7.9.5. SWOT analysis
7.10. Bayer Healthcare
7.10.1. Business overview
7.10.2. Financial data
7.10.3. Product landscape
7.10.4. Strategic outlook
7.10.5. SWOT analysis
7.11. Ionis Pharmaceuticals
7.11.1. Business overview
7.11.2. Financial data
7.11.3. Product landscape
7.11.4. Strategic outlook
7.11.5. SWOT analysis
